Iadademstat + SBRT With Atezo in ES-SCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Waga co najmniej 50 kg
- •Rozpoznanie raka płuca z małymi komórkami w stadium rozsianych przerzutów
- •Wcześniejsze leczenie chemioterapią zawierającą platynę
- •Stan ogólny pacjenta pozwalający na udział w badaniu (ECOG 0-2)
- •Przynajmniej jedno ognisko nowotworu możliwe do leczenia radioterapią
- •Dodatkowe ognisko nowotworu dostępne do biopsji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yale University
New Haven, United States
Trial contact
Ashley Yu
Stephanie Ladd
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.